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1. Introduction 
Systemic sclerosis (SSc) is characterized by a progressive fibrosis of the perivascular and 
interstitial connective tissues which can involve the skin, heart, lungs, kidneys, and the 
gastrointestinal tract. SSc is an uncommon, debilitating condition, associated to a vital risk 
linked to visceral extensions and has a high case-fatality rate among connectivitis. SSc 
begins in the vast majority of cases with a Raynaud’s phenomenon, may have a limited or 
diffuse skin extension, and is often associated to arterial occlusions, digital ulcerations or 
necrosis. SSc clinical manifestations are heterogeneous and classifications distinguish 
limited to diffuse disease, depending on the distribution of the skin lesions and organ 
involvement [1-3]. There is today no curative treatment. Disease susceptibility differs 
according to sex, age and race, there is a notable familial clustering, and SSc incidence may 
be rising [4, 5]. The clinical management of the patients still remains a difficult challenge 
and the pharmacopeia offers limited choices to the clinician to bring relief to patients. 
Pulmonary, renal and myocardial complications have benefited from the introduction of 
angiotensin converting enzyme inhibitors, calcium pump inhibitors, prostacyclin analogs 
and endothelin antagonists. Based on recent pathophysiological insights, a number of novel 
agents are being developed [6-8]. 
2. SSc pathogenesis in 2011: An elusive mechanism 
SSc pathogenesis remains obscure. Central features are an inflammatory vasculopathy, 
perivascular and interstitial sclerosis, altered angiogenesis and autoimmunity. Pathologic 
changes depend on whether they are observed at an early or late disease stage. The 
progression of the disease is typified by the accumulation of extra-cellular matrix (ECM) 
components in connective tissues. There are clinical and pathologic arguments to support 
the hypothesis that the vasculature is involved at an early step during disease progression.  
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Indeed, endothelium damage, perivascular edema and mononuclear cell infiltration are 
among earliest pathological changes that may precede the development of fibrosis [9-11]. 
Deregulated vascular tone, as evidenced by the Raynaud’s phenomenon and morphological 
abnormalities of nail-fold capillary loops, as evidenced by capillaroscopy, also witness the 
underlying vasculopathy. In such a hypothetical vascular perspective, endothelial cell (EC) 
injury fuels other manifestations of the disease by the way of a deregulated inflammatory 
reaction. Whatever the primary target, a putative sequence of events leading to progression 
of the disease may follows microvascular injury leading in turn to perivascular and 
interstitial inflammation, autoimmunity leading to further endothelium injury, chronic 
progression of the inflammatory reaction, activation of interstitial fibroblasts, pericytes and 
other fibrocompetent cells leading to myofibroblast generation and subsequent persistent 
fibrogenic response [6, 12-18]. There are arguments to incriminate the genetic background in 
the disease susceptibility and progression. Genetic studies have underlined the inherent 
complexity of the disease, highlighting the involvement of the vasculature, the immune 
system and the ECM.  Several polymorphisms in potential candidate genes have been 
identified [19-24]. The number of genes involved further underlines the disease spectrum 
heterogeneity. Environmental factors are linked to the disease, this being the case for 
exposure to silica, organic solvents or vinyl chloride. Infectious agents have been proposed 
to be involved, through endothelium damage, molecular mimicry-mediated autoimmune 
responses or other mechanisms [25, 26]. But how exposure to environmental risk factors 
combined to a permissive genetic background translates into initiation and progression of 
the disease is unclear. Therefore, fundamental questions remain currently unanswered with 
regard to key SSc features such as vascular, autoimmune and fibrotic events. The nature of 
the EC injury remains unknown. Several potential mechanisms have been explored, such as 
EC-specific T cells or auto-antibodies, vasculotropic viruses or environmental factors, 
oxidative stress, profibrotic and/or inflammatory cytokines. Altered angiogenesis is also a 
characteristic feature of SSc. Prevalent alterations of the capillary network in SSc include 
chaotic malformations with giant and bushy capillaries and reduced capillary density. There 
is, however, an insufficient angiogenic response, a defective vasculogenesis and a capillary 
loss in SSc [27]. Recent progresses have allowed progressive uncovering of the molecular 
mechanisms of tissue fibrosis. However, the widespread accumulation of ECM in SSc 
remain largely misunderstood, and therapeutic attempts to control fibrosis unfortunately 
remained unsuccessful [17, 18, 28-30]. 
3. SSc: A role for platelets? 
A recent expansion of knowledge from basic research has illuminated the role of platelets in 
the inflammatory signalization network and underlined a hitherto unsuspected role for 
platelets in inflammatory diseases. Moreover, platelets are linked to endothelium 
homeostasis. They have been implicated in several vascular and fibrotic disorders. Hence, 
platelets stand as foreseeable contributors to SSc natural history. Indeed, there are signs of 
ongoing platelet activation in SSc but the underlying mechanisms remain ill-defined. First, it 
is not known how platelets could be activated during the course of the disease, through 
endothelium injury, immunological mechanisms or other reasons; second, it is not clear 
which platelet-derived mediators may specifically influence the progression of the disease. 
In the following sections are summarized some of the mechanisms linking platelets with 
inflammation, angiogenesis, vascular tone and fibrosis. 
www.intechopen.com
 
Blood Platelets and Systemic Sclerosis 
 
31 
4. Platelets: Central actors of inflammation 
4.1 Platelets transport bioactive mediators in the bloodstream 
Platelets are cytoplasmic fragments that derive from the fragmentation of megakaryocytes 
(MKs) in the bone marrow sinuses. They harbor a unique store of secretory organelles 
having a distinct content in bioactive peptides. Alpha granules contain both soluble proteins 
destined to be secreted and membrane-bound proteins [31, 32]. Dense granules mostly 
contain an adenine nucleotide pool of ATP and ADP, bivalent cations calcium and 
magnesium and amines, including serotonin and histamine [33]. Platelet lysosomes contain 
a complex set of enzymes including acid proteases, such as cathepsin, carboxypeptidases, 
collagenases and various glycohydrolases [34]. Following platelet activation, the organelle 
content is released in a process termed secretion. The bulk of proteins secreted by platelets 
are remarkably large and diverse, as shown by proteomic studies on either platelet 
releasates or isolated granules. Classifications of the platelet secretome content with 
reference to biological effects pinpoint relations that platelets may encompass in various 
biological functions, including inflammation, tissue repair and angiogenesis [34-37]. Such a 
complexity has opened many new challenges with reference to the platelet role in human 
diseases. 
In addition to MK biosynthesis, platelets also carry mediators that are endocytosed from 
plasma and possibly concentrated and/or modified within platelets. Such a plasma uptake 
has, for example, been demonstrated for fibrinogen, albumin, immunoglobulins, amino 
acids, and several inflammatory mediators including vascular endothelial growth factor 
(VEGF), histamine or serotonin [38, 39]. Passive and/or active mechanisms are responsible 
for the platelet uptake of plasma material. Platelets may be considered as mobile nodes, 
gathering (through endocytosis) and imparting information to target cells [40]. Apart from 
the rapid mobilization and release of granule content, platelets also express biomediators, 
including IL-1, tissue factor, fibrinogen, thrombospondin, von Willebrand factor (vWF), 
GPIIb and GPIIIa, through a time-, translational-dependent pathway that is triggered upon 
platelet activation [41-45]. Finally, the traditional concept of platelet loss of function 
following activation is debated, as activated platelets circulate or persist in clots while 
keeping functional properties. 
4.2 Platelet-derived microparticles recapitulate essential platelet functions 
Activated platelets shed microparticles (MPs). Platelets are the major source of circulating 
MPs. MP biological roles recapitulate essential platelet functions as MPs represent a 
transport and delivery system of mediators participating to hemostasis, thrombosis, 
vascular repair and inflammation, acting both locally and systemically. MPs may transfer 
information to EC through adhesion and/or fusion, an event thought to contribute to the 
control of EC phenotype in inflammation [46-48]. 
4.3 Platelet-endothelium: A friend and foe relationship  
4.3.1 Platelets maintain vascular integrity 
One of the primary roles of platelets is to maintain vascular integrity [49]. At sites of 
vascular damage, platelets promptly adhere to exposed ECM [50], but also to activated EC 
(below), a first step in a sequence of events that result in platelet activation, initiation and 
propagation of hemostasis and thrombosis and in the release of key material contributing to 
wound repair and tissue regeneration, including ECM components and ECM remodeling 
proteins, matrix metalloproteinases (MMPs) and their inhibitors, the tissue inhibitors of 
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metalloproteinases (TIMPs). Platelets also provide essential material for the angiogenic 
process, as summarized below. The role of platelets in tissue repair goes beyond vascular 
integrity. Indeed, platelets are essential for organ repair and regeneration as remarkably 
exemplified in the liver [37, 51-53]. 
4.3.2 The platelet/endothelium dialogue in inflammation 
The dialogue between platelets and EC is a representative paradigm that has been 
extensively studied and reviewed because of its relevance in atherosclerosis [54]. Platelet-
ECs interactions are critical in the initiation and progression of vascular inflammation. 
Platelet-derived inflammatory mediators turn EC phenotype to proinflammatory and 
procoagulant, and platelets facilitate leukocyte recruitment through the endothelium by 
providing chemotactic signals and platelet-bound ligands [49, 54]. Platelets are brought to 
inflammatory sites through vascular leakage, attachment to leukocytes but they also 
respond to chemotactic signals [55]. Coagulation and inflammation are intricately linked, 
and platelets represent an integrating platform for coagulation and inflammation cascades. 
For example, they anchor the procoagulant complex leading to the generation of thrombin a 
potent proinflammatory mediator. Platelets also contribute to other inflammatory cascades; 
for example, they propagate complement system activation [56].  Further readings may be 
found in [49, 54, 57-59]. 
The inflammatory reaction leads to platelet activation. ECM components, chemokines, 
triggering of platelet receptors with ligands on inflammatory cells activate platelets. 
Importantly, activated ECs bind and activate platelets, and the underlying mechanisms have 
been recently précised [50]. In resting conditions, the endothelium is not adhesive for 
platelets and prevents platelet activation through multiple mechanisms [60]. Activated ECs 
support platelet adhesion and activation. Endothelium denudation, resulting in ECM 
exposure, is not a prerequisite for platelet activation. Indeed, platelets roll and adhere on 
activated ECs, as shown, for example, after stimulation with Tumor Necrosis Factor-, or 
following ischemia/reperfusion injury [61, 62]. EC activation (which can occurs through 
multiple mechanisms, inflammatory mediators, hypoxia, complement activation products, 
infectious agents...) results in the upregulation of adhesion molecules, including E- and P-
selectin, v3, intercellular adhesion molecule (ICAM)-1 or vWF, all ligands that mediate 
platelet rolling and firm adhesion in a process presenting profound analogies with the 
multistep-adhesion mechanisms of leukocytes on ECs [50, 54, 63-68]. Throughout the 
adhesion process platelets become activated. Activated platelets are a rich source of 
inflammatory mediators. They secrete a host of cytokines, chemokines, and lipid 
inflammatory mediators, deliver free acid arachidonic to bystander polymorphonuclear 
cells, allowing them to generate leukotriens. Activated platelets therefore contribute to 
generate a complex inflammatory milieu in their vicinity [37, 69, 70]. Platelet-derived 
inflammatory mediators deliver in turn activating signals to target cells including EC and 
leukocytes, resulting in the amplification of inflammation. 
4.4 Platelets are a source of angiogenesis mediators 
An important mechanism through which platelets control wound healing is linked to 
angiogenesis, as exemplified in tumor angiogenesis [71]. Platelets and platelet-derived MPs 
provide critical material for the generation and stabilization of the neo-angiogenic vessels; 
they secrete positive regulators and inhibitors of angiogenesis, including chemokines [72-
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78]. Platelets also link coagulation to angiogenesis, through the proteolytic release of several 
cryptic angiogenic regulators [79]. VEGF is a critical angiogenic mediator in SSc (below) and 
its connections with platelets have been extensively studied. VEGF is transported by 
platelets [80]. Following binding to its receptor, VEGF induces EC survival, growth, 
permeability and migration. Other key angiogenic regulators secreted by platelets are 
platelet-derived growth factor (PDGF), transforming growth factor, (TGF)- and 
angiopoietins. The angiogenic response is dependent on a complex regulated balance 
between the generation of pro- and anti-angiogenic molecules, with reference to magnitude 
and temporal production sequence [81]. The angiogenic activity of VEGF can only be 
appreciated by integrating the action of other mediators present in the EC environment [82, 
83]. PDGF, TGF- and angiopoietins are such mediators, acting in concert with VEGF for the 
stabilization of the vascular wall; their imbalanced expression has indeed been implicated in 
aberrant angiogenesis [82, 84]. Interestingly, there is a regulated differential secretion of pro- 
and anti-angiogenic mediators by platelets with reference to the nature of the agonist [85]. 
4.5 Platelet-derived mediators participate to vascular tone regulation 
The blood flow is dependent on the constriction/dilation of resistance arteries. Endothelium 
and periarterial autonomic nervous plexus provide essential controls of the vascular tone 
[86, 87]. ECs are a source of vasoactive mediators that regulate blood flow, including the 
relaxing factors nitric oxid (NO), prostacyclin (PGI2) or endothelium-derived 
hyperpolarizing factor and vasoconstrictive factors including thromboxane A2 or 
endothelin-1 [88, 89]. Recent progress has highlighted the involvement of platelets and 
platelet-derived MPs in the control of the vascular tone. The integrity of the endothelium 
appears central to the vasomotor response to platelets; on intact endothelium, platelet 
derived mediators, including serotonin and ADP, cause the release of relaxing factors by the 
endothelium. If endothelium dysfunction has occurred, the absence of its protective role 
allows platelet-derived mediators, including serotonin and thromboxan A2 to induce 
vasoconstriction by directly acting on smooth muscle cells [90, 91]. Interestingly, VEGF may 
prove to have an increasing importance in vascular flow regulation, apart from its role in 
angiogenesis. Recent evidences indicate that it preserves the structure and function of 
neuro-effectors junctions [87]. 
4.6 Platelets are a source of fibrogenic mediators 
Platelets are a rich source of pro-fibrotic molecules. Tissue fibrosis results from a 
deregulated wound-healing response to chronic injury. It is typically associated to a 
perpetuating inflammatory response, resulting for example from the persistence or repeated 
release of a tissue irritant, in contrast to the regulated acute inflammatory response that ends 
in a resolution step, repair of tissue damage and tissue homeostasis [92]. A central feature of 
tissue fibrosis is a quantitatively and qualitatively altered production of ECM. The increased 
biosynthesis of ECM components, particularly fibrillar collagens, by fibrocompetent cells 
contributes to generate a permanent and destructive tissue scarring that impairs organ 
function. Fibrocompetent cell  activation is therefore at the root of the natural history of 
tissue fibrosis, and one of its decisive manifestations is transdifferentiation towards 
myofibroblasts, expressing -smooth muscle actin (SMA), and harboring characteristic 
stress fibers and contractile phenotype [93]. It is generally accepted that the major source of 
myofibroblasts are local connective tissue fibroblasts. However, they can also be recruited 
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from circulating fibrocytes and bone marrow-derived mesenchymal precursors, or they 
can derive from local epithelial and endothelial cells through the epithelial-mesenchymal 
transition [94-99]. Multiple soluble signals activate fibrocompetent cells. Among the most 
studied in SSc are the growth factors TGF-1, PDGF, endothelin-1 and connective tissue 
growth factor. These mediators are potent fibroblast activators. TGF-1 holds a peculiar 
position in SSc, as its deregulated expression represents a critical step. TGF-1 promotes 
myofibroblastic transdifferentiation of quiescent fibroblasts, clearly demonstrated by the 
induction of -SMA [100], stimulates their proliferation and the synthesis of ECM 
components, including fibrillar collagens. Epithelial-mesenchymal transition is linked to 
inflammation and fibrosis and several pro-fibrotic mediators induce the epithelial-
mesenchymal transition [101]. A hierarchical induction of pro-fibrotic mediators in tissue 
fibrosis has been emphasized [102]. Chemokines, as monocyte chemotactic protein MCP-
1, RANTES (regulated upon activation, normal T-cell expressed and secreted), interleukin 
(IL)-8, activate fibrogenic cells, including skin fibroblasts, stimulating their proliferation, 
chemotaxis, and ECM biosynthesis. The interaction between keratinocytes and fibroblasts 
is a critical step during the early phase of wound healing in the skin. Fibroblasts produce 
keratinocyte growth factor and, conversely, keratinocytes signal to fibroblasts leading to 
their activation, production of a variety of cytokines/chemokines/angiogenic mediators, 
induction of ECM component synthesis and -SMA expression [102, 103]. There are 
important connections between vascular remodeling, angiogenesis and tissue fibrosis. 
Deregulated vascular remodeling is an important parameter in promoting the 
development of fibrosis and an imbalance between the production of angiogenic and 
antiangiogenic factors, such as CXC chemokines, at sites of tissue injury, is relevant to 
tissue fibrosis [17, 104-106]. Finally, a regulated balance between ECM production and 
degradation is a sine qua non condition for harmonious wound repair and tissue 
regeneration. Indeed, as shown in humans and in experimental tissue fibrosis models, the 
increased expression of some of TIMPs, a family of enzymes that control MMP activity 
through the inhibition of their proteolytic activity and the control of proform cleavage, 
leads to an altered MMP/TIMP balance, ECM homeostatic degradation/production 
disequilibrium, and ECM accumulation [107]. 
Platelets are essential actors in these mechanisms. They transport and secrete most of above 
–mentioned pro-fibrotic mediators, angiogenic and anti-angiogenic mediators, including 
CXC chemokines, ECM components and ECM remodeling proteins MMPs and TIMPs [108, 
109]. Platelets influence cell growth and differentiation in a variety of situations [110]. They 
provide key control signals to angiogenesis. Persistent platelet activation in the 
microvascular bed may therefore contribute to tissue fibrosis [111-113]. However, few 
studies have considered their potential contribution. In fact, platelet-derived mediators have 
only recently being acknowledged as being of key importance in fibrosis as observed in liver 
and pulmonary diseases and, very recently, in SSc (below). 
5. Evidence for platelet activation in SSc 
There are signs of platelet activation in SSc, as indicated by measurements of various 
soluble and membrane-bound markers, circulating MPs and platelet- and platelet-
leukocyte aggregates (Table 1). Soluble markers have been largely studied. As there are 
signs of ongoing EC injury in SSc, the specificity of these markers is an important point. P-
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selectin (CD62p) is a component of –granules and of intracellular EC storage organelles. 
There has been debate whether the increase in plasma CD62p truly reflects platelet 
activation, as it is also expressed on activated ECs. It is however currently clear that most, 
if not all, measured plasma CD62p has a platelet origin [114, 115]. Activated ECs have also 
been discussed as potential contributors to soluble CD154 (sCD154). In fact, correlation 
studies demonstrated that it can be considered as mostly derived from platelets [116], but, 
recently, other cell sources have been described, that may potentially contribute to 
elevated circulating sCD154 levels [117]. Soluble P-selectin glycoprotein ligand-1 is 
elevated in SSc [118], which may also reflect some degree of platelet activation as it is 
expressed by platelets [119]. Chemokine (C-X-C motif) ligand-4 (CXCL4, Platelet Factor 4) 
is elevated in SSc; albeit until recently described as exclusively derived from platelets, 
other sources exist such as T-cells or macrophages that may be contributors to elevated 
circulating levels [120]. Tissue-plasminogen activator (tPA) has also been described as a 
marker of EC damage [121]. Studies of the expression of platelet membrane-bound 
activation markers also show that platelets are not globally activated, but that this 
activation concerns a fraction of their population [122]. Correlation studies in general do 
not evidence relations with clinical features of the disease, but this is a matter of debate as 
correlations were found for some markers such as sCD154, thromboxane B2 or MPs (Table 
1). Finally, morphological electron microscopy-based studies also suggest platelet 
enhanced activability in SSc, and there are signs of platelet granule release [111, 123, 124]. 
A major point is that platelet activation may be prominently linked to the Raynaud’s 
phenomenon. Indeed, features of platelet activation are also found in the primary 
Raynaud’s phenomenon (below). 
 
Platelet activation markers 
Correlations with disease 
features 
References 
Circulating platelet 
aggregates 
Not found [125-127] 
Platelet-leucocyte aggregates Not found [128] [128] 
-TG Not found [122]; [130] [122]; [125-127]; [129-134];  
Serotonin Not found 
[135] (in the CREST 
variant); [136] (also in 
platelets)  
CXCL4 Not found 
[126]; [131]; [133]; Radstake 
Arthritis Rheum 2010;62 
Suppl 10 :1210 (Abstract); 
[134] 
Thromboxane B2 in plasma 
or urines (Thromboxane A2 
metabolite) 
Positive correlation with 
dSSc (Herrick 1996)  
[139] 
[134]; [137-139];  
TSP-1 Not found [133] 
tPA [132] 
Membrane CD62P Not found [122]; [128] 
Soluble CD62P Not found [140] 
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Platelet activation markers 
Correlations with disease 
features 
References 
sCD154 
Positive correlation with 
lSSc, with digital ulcers and 
pulmonary arterial 
hypertension [141] 
[141]; [142] 
Platelet-derived MPs 
Inverse correlation to the 
modified Rodnan thickness 
score [143] 
[128]; [143] 
Table 1. Markers of platelet activation in SSc 
Platelet activation in SSc is documented by several studies. Markers have been measured in 
plasma or serum or on platelets (CD62P). The elevation of circulating tPA is not always found 
[139, 144]. Abbreviations: -TG, -thromboglobulin ; TSP-1, thrombospondin-1 ; dSSc, diffuse 
cutaneous SSc; lSSc, limited cutaneous SSc ([2]). Other abbreviations are spelled in the text. 
6. Lack of platelet morphological abnormalities and count in SSc 
There are no specific recognized abnormalities of the platelet count in SSc. Moderate 
thrombocytosis or thrombocytopenia are occasionally observed, and have been related to 
inflammation or microangiopathy, respectively [145, 146]. Platelet morphology is not altered. 
7. Potential mechanisms mediating platelet activation in SSc 
Mechanisms underlying platelet activation in SSc remain ill-defined. Questions that have 
been pursued are: (i) is there a platelet dysfunction in patients that would reduce the 
threshold level of platelet response to activating signals? (ii) are platelets activated in SSc as 
the result of EC injury, autoantibodies directed at platelets or other reasons? (iii) what is the 
role played by the Raynaud’s phenomenon? 
7.1 Is there a platelet disorder in SSc leading to platelet hyperactivability? 
Several studies have examined the eventuality of platelet dysfunction in SSc (Table 2). 
Reports suggest augmented responsiveness of platelets to their physiological agonists, either 
strong agonists, such as thrombin or collagen, or weak agonists, such as serotonin, ADP, 
epinephrine or arachidonic acid, resulting in a reduced threshold of platelet aggregation to 
the agonist stimulus. Conversely, there is a reduced response to inhibitors of platelet 
activation such as prostacyclin. However, there are contradictory reports (Table 2). Platelet 
response to agonists as measured by the hyperactive phenotype is often difficult to 
interpret. There is a significant variability between individuals, as several genetic modifiers 
may influence platelet function and as platelet hyperactivity, as measured by aggregometry, 
can be detected in healthy individuals [147, 148]. Also, in vivo, platelet activation results 
from the combinational input of agonists that act in a complex synergistic way and vary 
from donor to donor [149-152]. The application of neural networks approaches for 
predicting platelet response to a complex milieu may represent a useful tool for studying 
platelet activation response to agonists in SSc. There are no straightforward interpretations 
of changes in platelet function in SSc. Interestingly, binding assays of radiolabelled collagen 
indicate a specific increase in the expression of the platelet collagen type 1 receptor in SSc 
patients [153], which would explain the enhanced response to collagen and indicate a 
www.intechopen.com
 
Blood Platelets and Systemic Sclerosis 
 
37 
primary or acquired defect. Proteomic studies on platelet compartments in SSc patients 
could help finding a potential primary or acquired platelet defects in this disease.  
 
Platelet function changes References 
Hyperaggregability 
Spontaneous (in whole blood) 
In response to agonists 
[126]; [131]; [154-158]  
Enhanced adhesion to collagen [159];  
Reduced sensitivity to PGI2 [160] 
Increased platelet sensitivity to collagen-
induced aggregation 
[138]; [157] 
Increased expression of collagen type 1 
receptor 
[153] 
Hyperaggregability not found [161] 
Table 2. Changes in platelet functions in SSc  
7.2 Potential mechanisms mediating platelet activation in SSc 
Platelet activation in SSc may first be the consequence of endothelium injury. Indeed, the 
canonical role of platelets is to react to endothelium damage, a circumstance that activates a 
bidirectional dialogue between ECs and platelets, initiating and sustaining inflammation. 
Through soluble and platelet-bound signals, activated platelets confer ECs a 
proinflammatory and procoagulant phenotype and, reciprocally, EC activation, as met in 
inflammation, leads to platelet activation resulting in a pro-inflammatory amplification 
loop. The balance of signals that keep platelet from being activated may be overcome in a 
variety of conditions. As summarized above, not only platelets react to the endothelial 
barrier loss of integrity with consequent exposure of the underneath collagen-rich matrix, 
but they also react to slighter features of EC activation, which do not lead per se to severe 
endothelium damage, as met for example in conditions in which ECs are activated by 
cytokines including TNF IL-1, VEGF, by oxidative stress or hypoxia [80, 162-165]. These 
signals induce the expression of a range of molecules promoting platelet adhesion on ECs. 
Platelets bind to these docking structures, an event that initiates their activation. These 
conditions also induce ECs to produce platelet agonists, such as multimeric vWF and ADP. 
Inflammation and coagulation are inextricably linked. Activated ECs express tissue factor, 
leading to the activation of coagulation, platelet activation, thrombin generation and further 
amplification of the inflammatory reaction. This is dramatically exemplified in renal 
involvement in SSc, characterized by thrombotic microangiopathy lesions. On electron 
microscopy studies, aggregates of platelets admixed with fibrin and fragmented red blood 
cells are observed within small interstitial vessels or glomerular capillaries. Hypoxia is a 
noxious stimulus that activates a range of inflammatory pathways, leading to EC activation 
through multiple mechanisms, including the production of angiogenic factors [166-168]. 
Hypoxia is thought to play a critical role in SSc. SSc-associated microangiopathy results in a 
disturbed blood flow in the capillaries with consequent hypoxia, which is likely to be 
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aggravated by tissue fibrosis [169-172]. Hypoxia alters vascular endothelium but also 
directly activates platelets [173, 174] (our unpublished results). Altogether, conditions that 
turn EC phenotype to proinfammatory/prothrombotic are translated into platelet adhesion 
and activation, with the consequent release of inflammatory, mitogenic, angiogenic and 
fibrogenic platelet-derived mediators described above. These mediators further activate 
ECs, promoting the production of cytokine/chemokines, induction of adhesion and 
procoagulant molecules, and production and activation of MMPs. Moreover, ECs 
undergoing apoptosis become proadhesive for platelets [175], and activated platelets can in 
turn induce EC apoptosis [176]. 
In fact, endothelial injury in the microcirculation and arterioles is a predominant feature of 
SSc which has extensively been reviewed [13, 30, 177-180]. There are circulating stigmata of 
endothelial injury, including von Willebrand factor and supranormal (larger) vWF 
multimers [126, 131, 139, 181-184], soluble adhesion molecules, such as E-selectin or vascular 
cell adhesion molecule (VCAM)-1 and ICAM-1, thrombomodulin, tPA, or endothelin [185-
188]. Increased nitrate in the plasma or serum of patients has been described, and been 
related to EC injury, as there are correlations with soluble E-selectin and soluble VCAM-1 
[189, 190]. Elevated circulating ECs were also attributed to vascular damage in SSc [191]. EC 
apoptosis is a common and early feature in SSc [192]; however pathologic evidence for EC 
apoptosis remains controversial [177]. However there are inherent limitations to the 
interpretations of such biomarkers [193], these results show that there is an early insult to 
the vasculature during the course of the disease. 
Importantly, the Raynaud’s phenomenon itself, one, if not the first manifestation of SSc, 
preceding the onset of other symptoms of the disease [194-198], is associated with platelet 
activation [132]. The absence of endothelium abnormalities in the primary Raynaud’s 
phenomenon is generally accepted, although limited morphological abnormalities have 
been described [199]. However, features of platelet activation are found in primary 
Raynaud’s phenomenon [158, 200, 201] and platelet activation was proposed to play a role 
in its pathogenesis [135, 202]. Therefore, events responsible for the Raynaud’s phenomenon 
lead to platelet activation in the absence of EC damage, a possible argument to place platelet 
activation as a very early pathogenic event in the reciprocal activation dialogue between 
platelets and ECs. Intriguingly, several factors that have been put forward as being 
potentially causative or susceptible to modify the progression of SSc, as exposure of 
extremities to cold, mechanical vibrations, exposure to organic solvents or silica, CMV 
infection are associated to some extent to platelet activation, and for some of them to trigger 
the Raynaud’s phenomenon. 
Finally, autoantibodies against platelet gpIIb/IIIa have been described in SSc [203]. 
However their role in platelet activation remains uncertain. 
8. Platelet activation and the progression of SSc 
SSc is a complex disease for which no specific causative mechanism has been identified.  The 
disease may be initiated in the vasculature, as morphological changes are apparent before 
the onset of the disease; however, it is not clear how endothelium injury begins. Platelets 
play a large and complex physiological role in health and disease, as they contribute to 
hemostasis, inflammation, tissue repair, and to the innate and adaptative immunity, 
standing as essential links [69, 204]. Platelets establish intimate bidirectional relationship  
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with the endothelium, making them potential contributors to SSc vasculopathy. The 
microcirculation is a characteristic target in SSc pathogenesis. Microcirculation 
hemorheologic conditions result in an intimate platelet/endothelium interface, 
characterized by a near capillary wall platelet concentration. Clearly, cross-interactions 
between ECs and platelets are inextricably linked under the form of feed-back activation 
loops and whether or not being a primary event, any condition leading to an endothelium 
insult drives platelet activation. Conversely, platelet activation drives to EC activation; the 
fact that platelet activation is observed in the primary Raynaud’s phenomenon, in the 
absence of EC detectable damage, may signify that subtle early events activating platelets, 
such as disturbed blood flow or hypoxia, precede the onset of the disease. Following platelet 
activation in the microcirculation, as described above, a wide array of soluble and platelet-
bound mediators with a pleiotropic range of actions are released that can contribute to 
several pathophysiological features of the disease including (i) vascular tone dysregulation, 
(ii) endothelium activation, (iii) inflammation, (iv) activation of the coagulation system, (v) 
fibrogenic response, (vi) altered angiogenesis. Apart from the possible deleterious cross-talk 
between endothelium and platelets, described above, two chief features of SSc progression 
that may be connected to platelets have been the subject of very recent reports. Altered 
angiogenesis and progressive perivascular and interstitial fibrosis are hallmarks of SSc [27]. 
First as summarized above, platelets are essential contributors to angiogenesis during 
wound healing, and ongoing platelet activation in capillary beds may be involved in the 
altered angiogenesis associated with SSc. In fact, in line with the major VEGF transporter 
role of platelets, platelet VEGF is increased in SSc patients. However, this is not the case for 
other angiogenic regulators, such as TGF-1, PDGF-BB or angiopoietins [122]. VEGF, jointly 
with other mediators, determines the angiogenic or non-angiogenic status of the EC and an 
imbalance between the relative concentrations of angiogenic mediators is likely to alter 
angiogenesis homeostasis [170, 177]. Indeed, the deregulated expression of VEGF is thought 
to lead to abnormal angiogenesis, as exemplified by the resulting disorganization of the 
capillary network with large, leaky, fragile capillaries; dynamic parameters, such as the 
magnitude or the kinetics of VEGF release being critically important [170, 205-207]. 
Therefore platelet activation in the patient’s microvascular beds may result in the release of 
inappropriate combinations of angiogenic and angiostatic mediators, and such 
disequilibrium may be relevant to the vascular disease in SSc [122, 208, 209]. Further, as 
summarized above, there are connections between angiogenesis, vascular remodeling and 
fibrosis and an unbalance between factors promoting and factors inhibiting angiogenesis 
may also be relevant to the progression of fibrosis. Second, as summarized above, platelets 
provide a cornucopia of mediators that may be relevant to the natural history of tissue 
fibrosis, i.e. through fibrocompetent cell activation. Sustained activation of fibrocompetent 
cells contribute to excessive ECM production in tissues. Indeed, fibroblasts expanded from 
the fibrotic skin or lungs from SSc patients have a myofibroblastic phenotype and there is a 
strong correlation between myofibroblast labeling in the lesional skin and the Rodnan skin 
score [210]. Crucial platelet links with tissue fibrosis have recently been emphasized in 
humans. In liver fibrosis the secretion of platelet-derived CXCL4 is instrumental [211]. In 
SSc, the role of platelet-derived serotonin in skin fibrosis is strongly suggested by the 
stimulation of the production of ECM by serotonin through binding to dermal fibroblasts 
serotonin receptor 5-HT2B, increased expression of 5-HT2B in the fibrotic skin of SSc patients 
and reduction of experimental fibrosis through pharmacological targeting of the 5-HT/5-
HT2B signaling and anti-platelet drugs [212]. 
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9. Conclusion; Platelet activation in SSc: A deleterious loop? 
The primary triggering event in SSc remains unclear. However, inflammation of the 
vasculature is a common denominator, whether resulting from an autoimmune response to 
a yet undefined antigen or other mechanisms. Whatever the primary target, inflammation 
leads to EC activation and, due to the reciprocal activating interplay between platelets and 
endothelium, EC activation in turn activates platelets and vice-versa. Platelet activation, 
through the release of cytokines, chemokines, angiogenic and chemotactic mediators...., 
amplifies the inflammatory reaction by triggering its many facets, including leukocyte 
recruitment, leading to further endothelium activation and perivascular inflammation, 
deregulated angiogenesis and, eventually, fibrosis (Figure 1). A chronic inflammatory 
scenario may contribute to fibrosis by the way of fibrocompetent cell activation, if the initial 
pathogenic trigger persists, either continuously or repetitively. Self-sustained myofibroblast-
dependent fibrotic process takes place on the grounds of a chronic inflammation. Platelets 
may therefore stand at an important place in the ill-understood hierarchy of cell and soluble 
mediators interplay responsible for the disease. This scenario is evidently highly simplified 
due to the extreme complexity and heterogeneity of the disease pathophysiology. The lack 
of suitable animal models [213, 214] that would accurately recapitulate each steps of SSc 
progression remains a real handicap to understand the natural history of this disease. 
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Fig. 1. Platelet activation in SSc: a deleterious loop? 
This schematic model underlines the potential role that platelets may play in the initiation 
and progression of SSc; see text for details. The role of platelet-derived MPs may also be an 
important point to consider, as they recapitulate several platelet functions and may transfer 
platelet deleterious effects at sites distant from their generation.  
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